Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Stockwatch: Pandora’s Interim Analysis

Executive Summary

The Medicines Company, Amarin and Geron have all reported interim analyses for clinical studies recently and investors have been left disappointed. Were we better off without the interim analysis?

You may also be interested in...



Stockwatch: What Links Actimmune And Vertex’s Event Horizon?

Drug failures in Phase III and value-based pricing were two forces affecting Horizon and Vertex, respectively, last week. Biogen and Teva have shown that value, at least, is a force to be argued with.

Stockwatch: Fanning The Embers Of M&A

A drug approval at Sarepta, two acquisitions by Allergan and $15bn worth of dry powder at Takeda has prompted “biotech off to the races” commentaries by analysts and the press. This froth will probably dissipate.

Imetelstat Study Blip Beats Geron’s Shares Down

Shares in Geron dropped by nearly 20% to $2.30 on NASDAQ on Sept. 12 following interim clinical data for its lead product, the anticancer imetelstat, from trials conducted by its partner Janssen.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC097315

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel